Abstract
PurposeThe aim of our study was to propose a strategy based on indocyanine green (ICG) (SBI) to provide better clinical guidelines for transarterial chemoembolization (TACE) treatments for Barcelona clinic liver cancer (BCLC) stage C hepatocellular carcinoma (HCC) patients.Materials and MethodsFrom October 2005 to December 2012, 112 BCLC stage C HCC patients initially treated with TACE were investigated, randomly divided into a training cohort (n = 79) and validation cohort (n = 33). In training group, the patients were grouped based on their 15 minutes ICG retention rate (ICG R15), different chemo drugs and dose of lipidol in TACE. Overall survival (OS) and progression‐free survival (PFS) were analyzed in subgroups. Strategy based on ICG was built and verified in validation group.ResultsFor those patients with ICG R15 values >10%, the lipiodol ≤10 mL group showed better survival than the lipiodol >10 mL group. For those patients with ICG R15 values ≤10%, the group that received triple‐drug chemotherapy treatments with lipiodol diameter ratio values between 1 and 3 showed better survival than the other group. Patients who conformed with the SBI had better survival times than those who did not conform with the SBI, in both the training cohort (median OS 10.3 vs 5.1 months; P < .001; median PFS, 3.3 vs 2.1 months; P = .006) and the validation cohort (median OS 8.9 vs 7.1 months; P = .087; median PFS, 6.6 vs 2.3 months; P < .001).ConclusionsThe SBI is suitable and may provide survival benefits for TACE treatments in BCLC stage C HCC patients.
Highlights
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, the sixth most common cancer, and the third leading cause of cancer‐related deaths worldwide.[1]
For patients classified as stage C of the Barcelona clinic liver cancer (BCLC) criteria, European and American guidelines recommend that the first line of treatment should be systemic but in everyday clinical practice, especially in Asia; due to the poor efficacy of systemic chemotherapy and the high costs of targeted drugs, Transarterial chemoembolization (TACE) remains the most common form of treatment and has demonstrated to effectively improve the prognosis of HCC patients.[2,3]
Patients who were diagnosed with HCC from October 2005 to December 2012 at the Sun Yat‐sen University Cancer Center (SYSUCC) and had TACE treatments as standard therapy were screened for eligibility
Summary
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, the sixth most common cancer, and the third leading cause of cancer‐related deaths worldwide.[1] Due to its insidious onset and high malignancy, HCC is often diagnosed at an intermediate or advanced stage and without a chance for radical resection. A standardized recommendation that can guide TACE treatment strategies in BCLC stage C HCC patients is necessary to improve their prognoses
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
